Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004500 · ClinicalTrials.gov registry record · Phase 3
Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome
A Phase 3 study, sponsored by Windtree Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 69
- Enrollment target
NCT00004500 is a Phase 3 study that was terminated before completion, run by Windtree Therapeutics. The registered enrollment target is 69 participants.
The verdict
NCT00004500, a Phase 3 study, was terminated before completion, sponsored by Windtree Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 69 participants
- Enrollment target
Study Summary
OBJECTIVES: Evaluate the safety and efficacy of lucinactant administered by bronchoalveolar lavage (BAL) in the treatment of meconium aspiration syndrome (MAS) in newborn infants.
Interventions
- OTHER Standard Care
- DRUG Lucinactant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2000-03 |
| Est. Completion | 2004-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004500
The ClinicalTrials.gov registry entry for NCT00004500 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Windtree Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard Care is the first listed.
NCT00004500 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004500 about?
NCT00004500 is a clinical study titled "Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome". OBJECTIVES: Evaluate the safety and efficacy of lucinactant administered by bronchoalveolar lavage (BAL) in the treatment of meconium aspiration syndrome (MAS) in newborn infants.
What is the current status of trial NCT00004500?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 69 participants. The study started on 2000-03. Estimated completion is 2004-11.
What interventions are being tested in trial NCT00004500?
The interventions under investigation include: Standard Care (OTHER), Lucinactant (DRUG).
Who is sponsoring clinical trial NCT00004500?
This trial is sponsored by Windtree Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.